Ircolon Forte (Trimebutine Maleate)

Trimebutine maleate acts on peripheral opioid receptors in the gut and modulates the enteric nervous system. By balancing smooth‑muscle activity, it stimulates under‑active segments and relaxes over‑active areas, restoring coordinated peristalsis without producing central opioid effects.

The prescribed dose of Ircolon Forte is determined by the treating physician based on the patient’s condition, severity, and response to therapy. Dosage may vary, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for trimebutine maleate in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Ircolon Forte, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with agents such as metoclopramide, trimebutine maleate offers a dual action—stimulating hypo‑motile segments while inhibiting hyper‑motile areas—without the dopamine‑antagonist‑related extrapyramidal side effects seen with metoclopramide. Its opioid‑receptor profile provides a distinct mechanism that may be preferable in certain functional GI disorders.

Ircolon Forte should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability and potency throughout its shelf life.

Ircolon Forte is taken orally, usually with a glass of water. It can be administered with or without food, but patients should follow the specific timing instructions given by their prescriber to achieve optimal therapeutic effect.

The most serious adverse reactions include severe allergic responses such as rash, angioedema or anaphylaxis, and rare cardiac arrhythmias. Patients experiencing any signs of these reactions should seek immediate medical attention and discontinue the medication.

Ircolon Forte is contraindicated in individuals with known hypersensitivity to trimebutine or any excipients, in patients with intestinal obstruction, severe hepatic impairment, or in those for whom prokinetic therapy is medically inappropriate. A healthcare professional should evaluate suitability before initiating treatment.